Latest news and press releases about NuCana plc (NCNA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform.
Price
| Price | $1.30 |
| Market Cap | $8M |
| Exchange | NASDAQ |
| Country | GB |
Valuation Ratios
| Price / Book | 0.23 |
| EV / EBITDA | 0.85 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -120.66% |
| Return on Invested Capital | -77.17% |
| Return on Assets | -98.39% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CASI · CLGN · CLSD · ENLV · GDTC · LSTA · MTVA
Explore sector: Healthcare · Biotechnology
More sections of NCNA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks